Altered cellular proton handling and cell volume regulation are hallmarks of tumorigenesis. To investigate a possible involvement of the non-gastric H +
Introduction
Accurate cellular proton handling is critical for controlling cell volume, cell proliferation, apoptosis, cell migration and senescence. Alterations in cell volume regulation and the regulation of the intra-and extracellular pH are hallmarks of tumorigenesis [1, 2] . Tumor proliferation results in areas with reduced glucose availability, hypoxia and extracellular acidification, which 1288 requires an adaptive up-regulation of glycolysis and cellular proton extrusion pathways including Na pumps on a functional and/or genetic level. This promotes the evolution of glycolytic, acid-resistant and highly infiltrative cancer cell phenotypes [1] . Low interstitial pH favors matrix protein degradation by membrane-bound or secreted proteinases, which increases cancer cell invasiveness, as shown for PC-3, and DU-145 prostate cancer cells, colorectal carcinoma cell lines and immortalized breast epithelial cells [3] [4] [5] . Proton export simultaneously causes intracellular alkalinization, which is critical for the oncogenic transformation of cells and the development/maintenance of transformed phenotypes. In NIH3T3 fibroblasts infected with the E7 oncogene of HPV16, or expressing the RAS oncogene, and in human keratinozytes, intracellular alkalinization was found to be specific for transformed cells and to be mediated by NHE1; in these cell types NHE1 inhibition prevented transformation and tumor cell proliferation. Similarly, in breast cancer cells a tumor-specific activation of Na + /H + exchanger, cell motility and invasion was observed [6, 7] . In microinvasive foci of breast cancer and adjacent intraductal cells NHE and glucose transporter 1 expression is up-regulated by hypoxia [1] . All these data suggest a prominent role of proton extrusion for preparing the 'soil' for tumor invasion, namely matrix degeneration on the one hand and the maintenance of transformed phenotypes by intracellular alkalinization on the other hand.
While the role of Na [19] . They comprise the gastric (HKalpha1) and the non-gastric (HKalpha2) isoform, the latter being encoded by gene ATP12A (ATP1AL1). Expression of ATP12A has been detected in the prostate, kidney, uterus, placenta, skin, brain and colon [20] . Specific functions are known in kidney and colon. Of note, ATP12A null mice display loss of luminal acidification and K + absorption in the prostate and kidney [21] [22] [23] , indicating that the pump acts as a functional H + /K + ATPase in vivo. Organism-wide profiling has shown differential expression of ATP12A mRNA in 88 human organism parts, 37 cell types, 39 cell lines and 78 disease states, with significant up-regulation in prostate-, and breast adenocarcinoma (EMBL-EBI arrayexpress archive, experiments E-MTAB-62, E-GEOD-24283, E-GEOD-6919; http://www.ebi.ac.uk). In human colorectal carcinoma ATP12A is significantly overexpressed, which eventually contributes to the development of the pathological condition [24] . In promyelocytic HL-60 cells and INS-1E rat insulinoma cells induction of apoptosis by butyrate is paralleled by ATP12A up-regulation ([13, 25] ; abstracts in this issue, manuscripts in preparation). Taken together, there is strong evidence for a role of ATP12A in the development of prostate cancer and possibly other disease states.
Given its functional role in the acidification of the prostate fluid in the normal prostate [23] and its altered expression during apoptosis in cancer cells, it is feasible to assume that ATP12A expression is also deranged in pathological prostate tissue. The aim of this study was to investigate ATP12A expression on the protein level and to test for differential ATP12A expression on the mRNA level in normal (tumor-free, TF) prostate tissue, benign prostate hyperplasia (BPH) and tumor stages I-III. To this end we have analyzed 26 formalin-fixed and paraffinembedded histological prostate sections of cancer patients by immunohistochemistry (IHC) and performed real-time quantitative PCR using a TissueScan TM prostate cancer disease array containing sets of tumor stages I-III, BPH and TF tissues. We demonstrate altered protein expression patterns in BPH as well as in tumor stages I-III. In contrast, no apparent differences in mRNA/cDNA amounts could be detected by RT-PCR in the samples investigated. We further show that ATP12A mRNA and protein is expressed in PC-3 and LNCaP prostate cancer cells, with a significantly higher mRNA expression level in LNCaP cells.
Materials and Methods

Immunohistochemistry
Experimental material and data handling: archived formalin-fixed and paraffin-embedded (FFPE) tissue blocks (histoblocks) provided by the Department of Pathology, General Hospital, Paracelsus Medical University Salzburg, were used for analyses. Experiments were performed in accordance with the Helsinki declaration of 1975 (revised 1983). All patients have signed an informed consent concerning the surgical removal and therapy of the tumors. The study did not extend to examination of individual case records. The anonymity of the patients was ensured.
1.5-µm sections were cut from FFPE tissue blocks with a Leica RM 2245 microtome, transferred onto microscope slides and deparaffinised using graded alcohol. Antigen retrieval was achieved by heat-induced epitope retrieval under pH 6.0 in antigen retrieval buffer (Dako) at 98°C for 30 minutes. Endogenous peroxidase blocking was carried out for 10 minutes with peroxidase-blocking reagent (Dako). Sections were then incubated for 30 minutes at room temperature with mouse primary antibodies directed against human ATP12A (Abnova). Primary antibodies were detected using the EnVision Detection System (Dako) employing biotinylated goat anti-mouse antibodies (1:100) and EnVision Dual Link System Peroxidase (Dako). Immunoreactivity was visualized using diaminobenzidine (DAB; Dako) as chromogenic substrate according to the manufacturer's instructions. Sections were counterstained with hematoxylin. The stained sections were digitalized using a Leica CTR 6000 Microscope. The majority of evaluated tissue sections contained more than one type of tissue/pathological state (lesion); normal (tumor-free) tissue, benign prostate hyperplasia, adenocarcinoma and atrophic tissue was present in 20, 18, 21 and 19 out of 26 sections, respectively. This allows for a direct, paired comparison of tumor free-and pathological tissues. The discrimination was performed microscopically and cancer staging was done according to the guidelines of the American Joint Committee on Cancer [26] . Images were analyzed using a modified quickscore method [27] . Briefly, this method takes into account the staining intensity (rated 0, 1, 2, or 3) and the relative amount of stained cells (based on 100 counted cells; 0=0-10%, 1=10-25%, 2=25-50%, 3=50-75%, 4=75-100%). Multiplication of staining intensity and extent yields scores ranging from 0-12, where scores from 0-3 are classified as negative, from 4-6 as weakly positive, from 7-9 as moderately positive, and from 10-12 as strongly positive (Fig. 2) .
Cell culture
LNCaP and PC-3 cells were cultured at 37°C, 5% CO 2 and 95% air in RPMI 1640 medium with L-glutamine (PAA Laboratories), and Ham F-12 medium (Sigma-Aldrich), respectively, supplemented with 10% fetal bovine serum (FBS; PAA Laboratories). Media contained 100 U/ml penicillin, 100 µg/ml streptomycin, and 250 ng/ml amphotericin B. Subcultures were established once a week by trypsin/EDTA treatment.
Western blot
The alpha2 subunit of the non-gastric H + /K + ATPase ATP12A was detected in LNCaP and PC-3 cell lysates by immunoblotting after growing cells for 2-3 days under standard conditions in 9-cm cell culture dishes. Cells were scraped off with lysis buffer composed of 150 mM NaCl, 50 mM TRIS-HCl (pH 7.5), 1 mM EGTA, 1% (v/v) Triton X-100, 0.1% (w/v) SDS and proteinase inhibitor cocktail containing AEBSF, pepstatinA, E-64, bestatin, leupeptin, aprotinin (Sigma-Aldrich). After brief sonication the cell lysates were centrifuged at 14,000×g for 10 minutes. The protein concentration in the supernatants was measured with a BCA (bicinchoninic acid) protein assay kit (Pierce-Thermo Scientific). 20 µl of supernatants (200 µg protein) mixed with 2× sample buffer containing 125 mM TRISHCl, 4% (w/v) SDS, 0.7% (v/v) β-mercaptoethanol, 20% (v/v) glycerol and 0.004% (w/v) bromphenol blue were separated by SDS-PAGE on an 8% Tris-glycin gels (peqlab). A prestained protein ladder (PageRuler, Fermentas) served as protein size marker. Proteins were transferred onto 1.2-µm nitrocellulose membranes (BIO-RAD). Immunodetection was performed with a polyclonal rabbit anti-ATP1AL1 primary antibody (SantaCruz Biotechnology) at a dilution of 1:200, a secondary biotinylated goat anti-rabbit antibody (1:300; Abcam), and Avidin-HRP (1:250; eBioscience). Blots were developed using SuperSignal ® West Pico Chemiluminescent Substrate (Pierce). Images were acquired using a BioSpectrum AC Imaging System and VisionWorks LS Software (UVP). 5'-AGGTCCAGACGCAGGATGGCATG-3'; fragment size 140 bp). Real-time PCR was run on an Mx3000P QPCR System (Agilent Technologies). The specificity of the PCR reactions was tested by melting curve analysis and by loading the amplification products on 2% agarose gels. Threshold cycles (Ct) were determined in the exponential amplification phase of the PCR reaction. Delta Ct (dCt) values were calculated by subtraction of the Ct values of beta-actin from the individual sample's Ct values [30] .
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Statistics
Data are presented as arithmetic mean ± standard error of the mean (SEM). Data were tested for Gaussian distribution using the Kolmogorov-Smirnov normality test and for outliers by the Grubb's test. Data were compared using 1-way ANOVA and Tukey's multiple comparison post-test, or unpaired t-test with Welsh's correction, as applicable. The significance level was 0.05 (95% confidence intervals). Analysis was done with GraphPad Prism 5 software.
Results
Immunohistochemistry
In normal (tumor-free) prostate tissue the alpha-subunit of the non-gastric H + /K + ATPase ATP12A is mainly observed at the plasma membrane and staining is dominant in basal cells (arrows) with punctual expression in clusters in some areas (Fig. 1A) . This clearly differs from the distribution pattern found under benign prostate hyperplasia (BPH; Fig. 1B ) and tumor tissues (Fig. 1C) , where immunoreactivity is increased, indicating increased ATP12A protein abundance with homogeneous expression in the whole epithelium. In tissues with BPH cell layers extend further into the acinus lumen and the cell mass is increased. In all types of tissue the stroma is negative for ATP12A (indicated by asterisks). Atrophic cells, probably undergoing apoptosis, appear ATP12A-negative (Fig. 1D) . Semi-quantitative analysis of the immunostained histological sections (n=26; Fig. 2) shows that in the majority of analyzed sections (13) tumor-free (TF) tissue is negative for ATP12A staining. In 7 sections TF tissue was weakly or moderately positive, whereas strongly positive staining was lacking. In both BPH and TU tissues immunoreactivity is increased, with a notable shift from negative and weakly positive towards strongly positive staining in the tumor tissue. In all analyzed sections containing atrophic tissue (19 out of 26) these areas were negative for ATP12A staining.
Quantitative real-time RT-PCR
QRT-PCR on a prostate cancer disease cDNA array shows expression of ATP12A in normal (tumorfree) human prostate, as well as in prostate cancer stage I-III and benign prostate hyperplasia. Individual delta Ct values (calculated as described in the Methods section) are plotted in Figure 3 . Mean dCt values for tumor-free samples (TF), prostate cancer stages I and II (TUI/II; pooled data), cancer stage III (TUIII), and benign hyperplasia (BPH) were 14.5 ± 0.8 (n=7), 14.1 ± 0.5 (n=19), 13.2 ± 1.2 (n=7), and 15.5 ± 0.3 (n=11), respectively. There were no statistically significant differences between the four groups. Gene expression studies on LNCaP and PC-3 prostate cancer cells yielded dCt values of 4.87 ± 0.13 (n=12) and 7.42 ± 1.09 (n=12), respectively (p=0.041) (Fig. 4A) . This amounts to a ~26-fold (25.6 ± 7.9-fold; n=12) higher expression in LNCaP cells as calculated from the ddCt values (according to 2^(dCt PC-3 -dCt LNCa ) [30] ).
Western blot
By using a primary antibody against the non-gastric H + /K + ATPase alpha-subunit (HKalpha2) we were able to detect specific bands at ~110 kDa in both LNCaP and PC-3 cells (Fig. 4B) . 
Discussion
As shown in this study in normal prostate tissue ATP12A is mainly restricted to basal cells and exhibits the highest immunoreactivity at or close to the cell membrane. Such localization is expected for a trans-membrane protein and indicates that ATP12A may indeed act as functional ion transporting H + /K + ATPase in intact prostate glands. Lobe-specific expression and apical localization for ATP12A has been demonstrated in rodent prostate where the function of the protein is necessary for the acidification of the semen [23, 31] . In contrast, ATP12A protein abundance is increased and the expression pattern of ATP12A is markedly altered in both in BPH and TU tissues compared to normal human prostate tissue. As evident, in these tissues total ATP12A immunoreactivity is increased and the protein is no longer restricted to the basal cells but can be found more homogenously throughout the epithelium. In addition ATP12A appears to be dispersed in the cytosol of the cells and does not exhibit preferential membrane localization ( Fig. 1 and 2) .
The deranged expression pattern might be due to altered transcription of the ATP12A gene. Of note, significant up-regulation of ATP12A is predicted for prostate adenocarcinoma from gene array studies (EMBL-EBI arrayexpress archive, experiments E-MTAB-62, E-GEOD-24283, E-GEOD-6919; http:// www.ebi.ac.uk). However, the results from our RT-PCR measurements using a cDNA library derived from normal, or defined pathological prostate tissue indicate that ATP12A mRNA expression is apparently unchanged in tumor tissue samples and BPH compared to normal tissue (Fig. 3) . Therefore it seems unlikely that the observed changes on the protein level arise from altered gene expression. However, even though the provided array samples are derived from pathologically clearly defined disease states, uncertainty arises concerning the absolute amount of lesion-specific mRNA/cDNA since the tissues from which the samples were derived from may contain more than one specific lesion at a time. For example, a tissue sample of stage III grading may also contain normal cells, atrophic cells or necrotic cells at varying degrees. So the total amount of mRNA/cDNA in such an array may not necessarily reflect the transcription of lesion-specific mRNA/cDNA.
The observed ATP12A expression pattern in pathological tissue could also arise from altered post-translational processing and/or sorting of the protein.
In MDCK and LLC-PK1 cells ATP12A is predominantly sorted to the apical and lateral membrane, respectively. This differential localization and sorting depends on the interaction of ATP12A with the beta-subunit of the Na + /K + ATPase [32] . Recently it has been shown that in the rat anterior prostate the Na + /K + ATPase beta1-subunit functions also as the authentic beta-subunit of the non-gastric H + /K + ATPase and putatively accounts for the intracellular sorting of the X-K-ATPase isoforms [33] . Interestingly, the Na + /K + ATPase beta1-subunit was found to be down-regulated by androgens in human LNCaP-FGC prostate cancer cells and human prostate cancer xenografts [34] . Similarly it has been shown that sorting of APT12A in stably transfected MDCK cells is regulated by protein kinase (PKC) and activation of PKC by phorbol esters causes internalization and intracellular accumulation of ATP12A [35] . Of note PKC regulation is markedly altered in prostate cancer [36, 37] . Therefore it is tempting to speculate that the alterations of ATP12A expression observed in this study might be due to deranged sorting of the protein as a consequence of tumor-driven altered expression of the Na + /K + ATPase beta1-subunit and/or PKC. In order to investigate gene transcription, post-translational processing, protein sorting and the cellular functions of ATP12A in detail, experiments need to be performed in functionally, morphologically and genetically defined cancer cell lines. As shown here, we find ATP12A gene and protein expression in both androgen-insensitive PC-3 and androgen-sensitive LNCaP cells, two well-established prostate cancer cell models. Interestingly ATP12A mRNA is more abundantly expressed in LNCaP cells (Fig. 4) 
